Daoyuan Wu

机构：Hong Kong University of Science and Technology, Henan Cancer Hospital

发表论文 16 篇 · 总被引 178 次 · h-index 8

代表论文

• Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial (2024 · 癌症：英文版 · 被引 47)
• Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer (2020 · Pathology - Research and Practice · 被引 34)
• LLM4Vuln: A Unified Evaluation Framework for Decoupling and Enhancing LLMs' Vulnerability Reasoning (2024 · arXiv (Cornell University) · 被引 19)
• Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance (2022 · Frontiers in Pharmacology · 被引 18)
• miR-199a-3p plays an anti-tumorigenic role in lung adenocarcinoma by suppressing anterior gradient 2 (2021 · Bioengineered · 被引 13)
• ACFix: Guiding LLMs With Mined Common RBAC Practices for Context-Aware Repair of Access Control Vulnerabilities in Smart Contracts (2025 · IEEE Transactions on Software Engineering · 被引 12)